BioXell S.p.A. and Lay Line Genomics S.p.A. have announced an exclusive, worldwide license agreement for the development of MNAC13, a humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor (NGF), a key mediator of pain.
According to the agreement, BioXell will take MNAC13 through development and potential commercialisation, in exchange for an undisclosed upfront payment, milestones and royalties to LLG.
MNAC13 belongs to a class of pain therapeutics that might represent a promising alternative to opioids such as morphine. Among its potential advantages are an improved safety profile and higher specificity which allow for improved efficacy and enhanced compliance.
"I am very proud of our team for moving MNAC13 to this advanced stage. We are extremely pleased that BioXell shares our excitement about MNAC13 and will be bringing its resources and expertise to the development of a novel potential pain therapeutic," said Antonino Cattaneo, President and CSO of LLG.
"This agreement further validates the power of LLG's antibody technologies and will allow us to concentrate our efforts on the development of LLG's Alzheimer's disease therapeutic and diagnostics programmes."
"This exciting programme perfectly fits into our pipeline and provides a near-term clinical development opportunity," said Francesco Sinigaglia, CEO of BioXell.
"NGF and its high affinity receptor TrkA are validated targets for pain, and we intend to explore the therapeutic potential of MNAC13 in specific conditions for which current therapeutic options are largely unsatisfactory."
"In addition to oncological pain and chronic inflammatory conditions such as osteoarthritis, we believe that MNAC13 may find an extremely promising field of application in Chronic Pelvic Pain Syndromes (CPPS), such as interstitial cystitis and chronic non-bacterial prostatitis."